US · Healthcare

Chemomab Therapeutics Ltd DRC (CMMB)

Biotechnology

Chemomab Therapeutics Ltd DRC (CMMB) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for CMMB

P/E ratio

25.00

Chemomab Therapeutics Ltd DRC (CMMB) — FAQ

What is CMMB's P/E ratio?

The price-to-earnings (P/E) ratio for Chemomab Therapeutics Ltd DRC (CMMB) is 25.00 (data as of 2026-05-23).

Does Chemomab Therapeutics Ltd DRC pay a dividend?

Dividend yield is not available in the current snapshot for Chemomab Therapeutics Ltd DRC (CMMB). Check the MyAverix Finance app for the latest dividend data.

What sector is Chemomab Therapeutics Ltd DRC in?

Chemomab Therapeutics Ltd DRC (CMMB) is classified in the Healthcare sector (Biotechnology industry).

What exchange is CMMB listed on?

CMMB is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)